MedTrace Logo

Endothelial Facilitation in Alzheimer's Disease

NCT01439555 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2019-07-30

Study results available
· View outcomes & findings →

Summary

Purpose of the study: Patients with mild Alzheimer's Disease will be given three different drugs over a 4-month period to try to increase the blood flow to their brains, and improve blood vessel and brain function. Each drug can help to open the blood vessels in the brain, and together they may be more effective than each drug alone. The hypothesis is that small blood vessels secrete substances that maintain the integrity of the brain, and may prevent loss of nerve cells leading to Alzheimer's Disease

Conditions

Interventions

DRUG

Simvastatin

Simvastatin, 40 mg per day orally

DRUG

L-Arginine

L-Arginine, 2 Gm four times per day orally;

DRUG

Tetrahydrobiopterin

Tetrahydrobiopterin 20 mg/kg/day orally

Sponsors & Collaborators

  • The Glass Foundation

    collaborator UNKNOWN

  • University of Massachusetts, Worcester

    lead OTHER

Principal Investigators

  • Elizabeth R DeGrush, DO · UMass Medical School

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
55 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2017-11-30
Completion
2017-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01439555 on ClinicalTrials.gov